Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-Trp53+/- mice

Breast Cancer Research

Volumn 10, Issue 3, 2008, Pages

  Dunphy, Karen A ^a   Blackburn, Anneke C ^a,b   Yan, Haoheng ^a   O'Connell, Lauren R ^a   Jerry, D Joseph ^a,c  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b Biology and Environment   (Australia)

^c Pioneer Valley Life Sciences Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; PLACEBO; PROGESTERONE; PROTEIN P53;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; DISEASE MODEL; DNA DAMAGE; EXPERIMENTAL NEOPLASM; FAMILIAL CANCER; FEMALE; GENETICS; METABOLISM; MOUSE; PHYSIOLOGY;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; DNA DAMAGE; ESTROGENS; FEMALE; LI-FRAUMENI SYNDROME; MAMMARY NEOPLASMS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; PLACEBOS; PROGESTERONE; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 55749090657     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2094     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001, 344:276-285. 10.1056/NEJM200101253440407, 11172156.
3. Travis RC, Key TJ. Oestrogen exposure and breast cancer risk. Breast Cancer Res 2003, 5:239-247. 314432, 12927032, 10.1186/bcr628.
4. MacMahon B, Cole P, Lin TM, Lowe CR, Mirra AP, Ravnihar B, Salber EJ, Valaoras VG, Yuasa S. Age at first birth and breast cancer risk. Bull World Health Organ 1970, 43:209-221.
5. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol 1994, 139:819-835.
6. Sinha DK, Pazik JE, Dao TL. Prevention of mammary carcinogenesis in rats by pregnancy: effect of full-term and interrupted pregnancy. Br J Cancer 1988, 57:390-394.
7. Sivaraman L, Stephens LC, Markaverich BM, Clark JA, Krnacik S, Conneely OM, O'Malley BW, Medina D. Hormone-induced refractoriness to mammary carcinogenesis in Wistar-Furth rats. Carcinogenesis 1998, 19:1573-1581. 10.1093/carcin/19.9.1573, 9771927.
8. Cabanes A, Wang M, Olivo S, deAssis S, Gustafsson JA, Khan G, Hilakivi-Clarke L. Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis. Carcinogenesis 2004, 25:741-748. 10.1093/carcin/bgh065, 14729590.
9. Grubbs CJ, Farnell DR, Hill DL, McDonough KC. Chemoprevention of N-nitroso-N-methylurea-induced mammary cancers by pretreatment with 17 beta-estradiol and progesterone. J Natl Cancer Inst 1985, 74:927-931.
10. Yu MC, Gerkins VR, Henderson BE, Brown JB, Pike MC. Elevated levels of prolactin in nulliparous women. Br J Cancer 1981, 43:826-831.
11. Thordarson G, Jin E, Guzman RC, Swanson SM, Nandi S, Talamantes F. Refractoriness to mammary tumorigenesis in parous rats: is it caused by persistent changes in the hormonal environment or permanent biochemical alterations in the mammary epithelia?. Carcinogenesis 1995, 16:2847-2853. 10.1093/carcin/16.11.2847, 7586208.
12. Musey VC, Collins DC, Musey PI, Martino-Saltzman D, Preedy JR. Long-term effect of a first pregnancy on the secretion of prolactin. N Engl J Med 1987, 316:229-234.
13. Bridges RS, Byrnes EM. Reproductive experience reduces circulating 17beta-estradiol and prolactin levels during proestrus and alters estrogen sensitivity in female rats. Endocrinology 2006, 147:2575-2582. 10.1210/en.2005-0917, 16484327.
14. Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 1982, 2:5-73. 10.1007/BF01805718, 6216933.
15. Guzman RC, Yang J, Rajkumar L, Thordarson G, Chen X, Nandi S. Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy. Proc Natl Acad Sci USA 1999, 96:2520-2525. 26817, 10051675, 10.1073/pnas.96.5.2520.
16. Haslam SZ, Woodward TL. Host microenvironment in breast cancer development: epithelial-cell-stromal-cell interactions and steroid hormone action in normal and cancerous mammary gland. Breast Cancer Res 2003, 5:208-215. 165024, 12817994, 10.1186/bcr615.
17. Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C. The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci 2004, 117:1495-1502. 10.1242/jcs.01000, 14996910.
18. McDaniel SM, Rumer KK, Biroc SL, Metz RP, Singh M, Porter W, Schedin P. Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am J Pathol 2006, 168:608-620. 1606507, 16436674, 10.2353/ajpath.2006.050677.
19. Blakely CM, Stoddard AJ, Belka GK, Dugan KD, Notarfrancesco KL, Moody SE, D'Cruz CM, Chodosh LA. Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy. Cancer Res 2006, 66:6421-6431. 10.1158/0008-5472.CAN-05-4235, 16778221.
20. D'Cruz CM, Moody SE, Master SR, Hartman JL, Keiper EA, Imielinski MB, Cox JD, Wang JY, Ha SI, Keister BA, Chodosh LA. Persistent parity-induced changes in growth factors, TGF-beta3, and differentiation in the rodent mammary gland. Mol Endocrinol 2002, 16:2034-2051. 10.1210/me.2002-0073, 12198241.
21. Sivaraman L, Conneely OM, Medina D, O'Malley BW. p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. Proc Natl Acad Sci USA 2001, 98:12379-12384. 60062, 11606748, 10.1073/pnas.221459098.
22. Jerry DJ, Kittrell FS, Kuperwasser C, Laucirica R, Dickinson ES, Bonilla PJ, Butel JS, Medina D. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene 2000, 19:1052-1058. 10.1038/sj.onc.1203270, 10713689.
23. Medina D, Kittrell FS. p53 function is required for hormone-mediated protection of mouse mammary tumorigenesis. Cancer Res 2003, 63:6140-6143.
24. Land CE, Boice JDJ, Shore RE, Norman JE, Tokunaga M. Breast cancer risk from low-dose exposures to ionizing radiation: results of parallel analysis of three exposed populations of women. J Natl Cancer Inst 1980, 65:353-376.
25. Tokunaga M. Breast cancer among atomic bomb survivors: relationship of prognosis to pathologic findings. Acta Pathol Jpn 1979, 29:197-209.
26. Minter LM, Dickinson ES, Naber SP, Jerry DJ. Epithelial cell cycling predicts p53 responsiveness to gamma-irradiation during post-natal mammary gland development. Development 2002, 129:2997-3008.
27. Becker KA, Lu S, Dickinson ES, Dunphy KA, Mathews L, Schneider SS, Jerry DJ. Estrogen and progesterone regulate radiation-induced p53 activity in mammary epithelium through TGF-beta-dependent pathways. Oncogene 2005, 24:6345-6353.
28. Nichols KE, Malkin D, Garber JE, Fraumeni JF, Li FP. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001, 10:83-87.
29. Kleihues P, Schauble B, zur HA, Esteve J, Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 1997, 150:1-13. 1858532, 9006316.
30. Mori N, Yamate J, Umesako S, Hong DP, Okumoto M, Nakao R. Preferential induction of mammary tumors in p53 hemizygous BALB/c mice by fractionated irradiation of a sub-lethal dose of X-rays. J Radiat Res (Tokyo) 2003, 44:249-254. 10.1269/jrr.44.249, 14646229.
31. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000, 19:968-988. 10.1038/sj.onc.1203277, 10713680.
32. Kuperwasser C, Hurlbut GD, Kittrell FS, Dickinson ES, Laucirica R, Medina D, Naber SP, Jerry DJ. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice: a model for Li-fraumeni syndrome. Am J Pathol 2000, 157:2151-2159. 1885755, 11106587.
33. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002, 1:289-298. 10.1016/S1535-6108(02)00047-8, 12086865.
34. Rajkumar L, Kittrell FS, Guzman RC, Brown PH, Nandi S, Medina D. Hormone-induced protection of mammary tumorigenesis in genetically engineered mouse models. Breast Cancer Res 2007, 9:R12. 1851398, 17257424, 10.1186/bcr1645.
35. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006, 127:1323-1334. 10.1016/j.cell.2006.12.007, 17182091.
36. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660. 10.1038/nature05529, 17251933.
37. Colombel M, Radvanyi F, Blanche M, Abbou C, Buttyan R, Donehower LA, Chopin D, Thiery JP. Androgen suppressed apoptosis is modified in p53 deficient mice. Oncogene 1995, 10:1269-1274. 7731676.
38. Lynch CJ, Milner J. Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency. Oncogene 2006, 25:3463-3470. 10.1038/sj.onc.1209387, 16449974.
39. Santarosa M, Ashworth A. Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim Biophys Acta 2004, 1654:105-122.
40. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 2006, 8:R43. 1779465, 16859501, 10.1186/bcr1525.
41. Lin SC, Lee KF, Nikitin AY, Hilsenbeck SG, Cardiff RD, Li A, Kang KW, Frank SA, Lee WH, Lee EY. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res 2004, 64:3525-3532. 10.1158/0008-5472.CAN-03-3524, 15150107.
42. Lewandowski SA, Thiery J, Jalil A, Leclercq G, Szczylik C, Chouaib S. Opposite effects of estrogen receptors alpha and beta on MCF-7 sensitivity to the cytotoxic action of TNF and p53 activity. Oncogene 2005, 24:4789-4798. 10.1038/sj.onc.1208595, 15870704.
43. Sayeed A, Konduri SD, Liu W, Bansal S, Li F, Das GM. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res 2007, 67:7746-7755. 10.1158/0008-5472.CAN-06-3724, 17699779.
44. Matulka LA, Triplett AA, Wagner KU. Parity-induced mammary epithelial cells are multipotent and express cell surface markers associated with stem cells. Dev Biol 2007, 303:29-44. 10.1016/j.ydbio.2006.12.017, 17222404.
45. Wagner KU, Boulanger CA, Henry MD, Sgagias M, Hennighausen L, Smith GH. An adjunct mammary epithelial cell population in parous females: its role in functional adaptation and tissue renewal. Development 2002, 129:1377-1386.
46. Britt K, Ashworth A, Smalley M. Pregnancy and the risk of breast cancer. Endocr Relat Cancer 2007, 14:907-933. 10.1677/ERC-07-0137, 18045947.
47. Reichmann E, Ball R, Groner B, Friis RR. New mammary epithelial and fibroblastic cell clones in coculture form structures competent to differentiate functionally. J Cell Biol 1989, 108:1127-1138. 2115403, 2466037, 10.1083/jcb.108.3.1127.
48. Wicha MS. Interaction of rat mammary epithelium with extracellular matrix components. Prog Clin Biol Res 1984, 145:129-142.
49. Maffini MV, Calabro JM, Soto AM, Sonnenschein C. Stromal regulation of neoplastic development: age-dependent normalization of neoplastic mammary cells by mammary stroma. Am J Pathol 2005, 167:1405-1410. 1603788, 16251424.
50. Taddei I, Faraldo MM, Teuliere J, Deugnier MA, Thiery JP, Glukhova MA. Integrins in mammary gland development and differentiation of mammary epithelium. J Mammary Gland Biol Neoplasia 2003, 8:383-394. 10.1023/B:JOMG.0000017426.74915.b9, 14985635.
51. Woodward TL, Mienaltowski AS, Modi RR, Bennett JM, Haslam SZ. Fibronectin and the alpha(5)beta(1) integrin are under developmental and ovarian steroid regulation in the normal mouse mammary gland. Endocrinology 2001, 142:3214-3222. 10.1210/en.142.7.3214, 11416044.
52. Faraldo MM, Deugnier MA, Thiery JP, Glukhova MA. Growth defects induced by perturbation of beta1-integrin function in the mammary gland epithelium result from a lack of MAPK activation via the Shc and Akt pathways. EMBO Rep 2001, 2:431-437. 1083881, 11375936.